John Rogers Increases Stake in Prestige Consumer Healthcare Inc
On June 30, 2026, John Rogers (Trades, Portfolio) executed a notable transaction involving Prestige Consumer Healthcare Inc (PBH). The transaction saw an additi
Prestige Consumer Healthcare Inc. Common Stock (PBH) is currently showing a bearish headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
On June 30, 2026, John Rogers (Trades, Portfolio) executed a notable transaction involving Prestige Consumer Healthcare Inc (PBH). The transaction saw an additi
TARRYTOWN, N.Y., July 06, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) (“Prestige”) today announced that it has closed the previously announced acquisition of LaCorium Health (“LaCorium”), priced a private offering of $400 million in senior notes, and will report its first quarter fiscal 2027 results on August 6, 2026.
This under-the-radar healthcare stock just made its biggest acquisition ever -- and it could easily outperform many of Wall Street's favorite names.






This section is separated from the general news feed so investors can quickly connect the latest headlines with the structured earnings report.

TARRYTOWN, N.Y., July 06, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) (“Prestige”) today announced that it has closed the previously announced acquisition of LaCorium Health (“LaCorium”), priced a private offering of $400 million in senior notes, and will report its first quarter fiscal 2027 results on August 6, 2026.

SAN FRANCISCO, June 25, 2026 /PRNewswire/ -- Investors in Prestige Consumer Healthcare (NYSE: PBH) saw the price of their shares fall over 11% on May 14, 2026 after the company revealed significant revenue declines and production problems driving the company's disappointing Q4 2026 financial results. The surprise developments have prompted national shareholder rights firm Hagens Berman to open an investigation into whether, before May 14, Prestige was sufficiently transparent regarding its ability to remediate supply chain constraints and, if not, whether the company violated the federal securities laws.
Generate a short AI read that goes beyond the headlines above, plus a plain-English breakdown of what it could mean going forward.